“LONG COVID”-A hypothesis for understanding the biological basis and pharmacological treatment strategy
"LONG COVID"-생물학적 기초 및 약리학적 치료 전략 이해를 위한 가설
Review
Published on
Journal: Pharmacology Research & Perspectives [Category] COVID19(2023년), MERS, SARS, 바이오마커, 신약개발, 치료제,
Journal: Pharmacology Research & Perspectives [Category] COVID19(2023년), MERS, SARS, 바이오마커, 신약개발, 치료제,
[키워드] “LONG COVID”.
ACE-2
activate
activator
antioxidant
Asymptomatic
battery
binding
biological basis
blood vessel
blood vessels
cause
clinical study
clinical trial
Cohort
cough
COVID-19
cytokine
Depression
diagnosed
disease
drug
elevated
eliminated
Endothelial cell
endothelial cells
Endothelium
enzyme
Enzymes
evaluate
expression
fatigue
free radical
Free radicals
glutathione
Human
Hypothesis
hypoxia
Inflammation
Insomnia
longitudinal
Loss of Smell
loss of smell and/or taste
marker
melatonin
non-infected
normal activity
Nrf2
nuclear
option
oxidative
oxidative stress
oxygen
Pain
pathology
pharmacological treatment
proportion
Protein
reactive oxygen species
replicate
Replication
required
Safe
SARS-CoV-2
SARS-CoV-2 virus
severe pneumonia
Shortness of breath
subject
subjects
Symptom
Symptoms
syndrome
Tachycardia
Taste
these cell
These cells
tissue
tissue hypoxia
transcription factor
variety
Viral
viral replication
virus
were infected
[DOI] 10.1002/prp2.911 PMC 바로가기 [Article Type] Review
[DOI] 10.1002/prp2.911 PMC 바로가기 [Article Type] Review